News from imaginab, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 28, 2021, 03:00 ET ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology

ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation...

Jan 07, 2021, 03:00 ET ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license...

Dec 09, 2019, 05:00 ET ImaginAb Initiates Phase II Clinical Trial at Penn Medicine

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8...

Oct 14, 2019, 02:00 ET ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with...

Oct 09, 2019, 09:20 ET ImaginAb To Present At Innovation Showcase 2019 Hosted By The Lundquist Institute

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, today announces that its Chief Executive Officer, Ian Wilson, will present an...

Oct 08, 2019, 09:21 ET ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology...

Sep 25, 2019, 07:30 ET ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going "Base Line/On Therapy" (BOT) Phase II Clinical Trial

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of ...

Sep 04, 2019, 08:00 ET ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following...

Jun 20, 2019, 15:24 ET ImaginAb to Present at SNMMI 2019 Annual Meeting

ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it will attend and present at the upcoming Society of Nuclear...

May 30, 2019, 04:00 ET ImaginAb to Present at Upcoming Investor and Scientific Conferences in May and June 2019

ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it is scheduled to present at the following investor and...

Feb 26, 2019, 07:30 ET ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board

ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Ian Wilson as Chief Executive Officer while...

Jan 18, 2019, 07:00 ET ImaginAb Enrolls First Patient in Phase II Clinical Trial

ImaginAb, Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of...

Jan 03, 2019, 07:00 ET ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics

ImaginAb Inc., an immuno-oncology imaging company, today announced that it has entered into a non-exclusive license and clinical trial collaboration...

Jan 02, 2019, 07:00 ET ImaginAb Announces Strengthening of Board and Executive Leadership Team

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Friedhelm Blobel, Ph.D., former President and...

Oct 08, 2018, 07:00 ET ImaginAb Announces Collaboration with Merck for CD8 T cell I/O Imaging Agent

ImaginAb Inc., an emerging immuno-oncology imaging company, today announced that it has entered into a multi-year, non-exclusive licensing...

Aug 29, 2018, 07:30 ET ImaginAb and CPDC Announce Clinical Trial Supply Manufacture and Distribution Agreement for ImaginAb's CD8 Immuno PET Tracer

ImaginAb, Inc., an immuno-oncology imaging company, and Centre for Probe Development and Commercialization (CPDC), a Canadian centre of excellence...

Jun 22, 2018, 07:30 ET ImaginAb Reconstitutes Japanese Subsidiary

ImaginAb, Inc. announced today new directors of ImaginAb Japan KK, a wholly-owned subsidiary of Los Angeles-based ImaginAb, Inc. Headquartered in...

May 17, 2018, 07:00 ET ImaginAb Reconstitutes Scientific Advisory Board

ImaginAb Inc., an immuno-oncology imaging company, today announced the reconstitution of its Scientific Advisory Board (SAB) comprised of foremost...

Feb 06, 2018, 07:00 ET ImaginAb Appoints Ian Wilson as Chief Operating Officer

ImaginAb Inc., an immuno-oncology imaging company, today announced the appointment of Ian Wilson as the company's Chief Operating Officer. Mr. Wilson ...

Jun 05, 2015, 06:08 ET ImaginAb's Prostate Imaging Phase I/IIa data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, alongside pre-clinical CD3+ T-cell imaging data

Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting ImaginAb's Phase I/IIa clinical imaging data with IAB2M in patients with...

Sep 17, 2014, 09:07 ET ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging

ImaginAb, Inc. today announced that it has entered into an exclusive technology development partnership with Novotectid GmbH for the development of...

Jul 28, 2014, 08:00 ET ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development

ImaginAb, Inc. today announced today announced that it has appointed Roger Crystal, MD as Vice President of Business Development. Dr. Crystal most...

Jun 10, 2014, 04:00 ET NCM and ImaginAb Ink Clinical Isotope Supply and Labeling Agreement

NCM USA announced today it has signed a long-term clinical zirconium isotope (89Zr) supply and cGMP biologics labeling agreement with ImaginAb, Inc., ...

Jun 09, 2014, 08:00 ET ImaginAb Partners with IBA Molecular for Clinical Supply of 89Zr Labeled Drug Product

ImaginAb, Inc. (ImaginAb) and IBA Molecular North America, Inc. (IBA Molecular) announced that IBA Molecular has been selected to provide...

Jun 06, 2014, 08:00 ET ImaginAb Presents Initial Phase I/IIa Results for Prostate Imaging Agent at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA...